Main Article Content
ocular surface disease, amniotic membrane, sutureless
Treatments for ocular surface disease have evolved significantly over the past several years. Sutureless amniotic membranes are easy to insert in the office, and they give practitioners the ability to monitor healing without interfering with the penetration of ophthalmic medications. With their ability to reduce inflammation, prevent scarring, and enhance epithelial proliferation, AM should be considered as a viable treatment option for managing patients with ocular surface disease.
2. Rennie K, Gruslin A, Hengstschla¨ger M, et al. Applications of amniotic membrane and fluid in stem cell biology and regenerative medicine. Stem Cells Int 2012; 2012:721538.
3. Kubo M, Sonoda Y, Muramatsu R, Usui M. Immunogenicity of human amniotic membrane in experimental xenotransplantation. Invest Ophthalmol Vis Sci 2001; 42:1539–1546.
4. Tseng SCG, Espana EM, Kawakita T, et al. How does amniotic membrane work? Ocul Surf 2004; 2:177–187.
5. Pachigolla G, Prasher P, Di Pascuale MA, et al. Evaluation of the role of ProKera in the management of ocular surface and orbital disorders. Eye Contact Lens 2009; 35:172–175.
6. Ijiri S1, Kobayashi A, Sugiyama K, et al. Evaluation of visual acuity and color vision in normal human eyes with a sutureless temporary amniotic membrane patch. Am J Ophthalmol. 2007;144(6):938-942.